ReviewFrontiers in surgery2026
New insights from MRI-guided laser interstitial thermal therapy for refractory epilepsy: a state-of-the-art overview.
Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recently, MRI-guided laser interstitial thermal therapy (MRgLITT) has emerged as a therapeutic option for drug-resistant epilepsy (DRE). However, the absence of standardized clinical guidelines remains a significant issue. Objective: To conduct a systematic review of systematic reviews to provide a descriptive assessment of the quality of evidence regarding the application of MRgLITT for DRE. Methods: We conducted a comprehensive search in PubMed, Embase, Scopus, Web of Science, Cochrane Library, and Google Scholar up to May 30th, 2024. We evaluated the risk of bias in each study using the AMSTAR-2 tool. The primary outcomes assessed were seizure freedom and perioperative or postoperative complications rate, while the secondary outcome was reoperation rate. The certainty of the evidence was appraised using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. Finally, pertinent findings were illustrated in a bubble plot. Results: A total of 16 systematic reviews met eligibility criteria, just including observational studies (cohorts and case series). Fourteen SRs scored "Critically low" with a median 8 [IQR: 5.25-8.25]. Seizure freedom rate ranged from 18.87% to 75.86%, and the most frequent cause of DRE was mesial temporal lobe epilepsy. The most common complications were visual field deficit (2.17%-7.5%) and intracranial hemorrhage (0.96%-8.6%). All the outcomes reported a "very low" certainty of evidence, as randomized studies were absent in the reviews. Conclusion: This overview provides comprehensive evidence on the application of MRgLITT for DRE). The evidence indicates a seizure freedom rate ranging from 18.87% to 75.86% with certainty levels raning from critically low to low. While these findings are promising, further primary and secondary studies are essential to establish definitive conclusions and assess the potential for future clinical applications or recommendations. Protocol Registration Number: CRD42022339024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.